Abstract
To test the hypothesis that excess amyloid deposition is an essential step in the pathophysiology of Alzheimer’s disease appropriate biomarkers are essential in selecting agents that modify amyloid formation or clearance. Cerebrospinal fluid concentrations of relevant analytes and PET measures of total brain load have been developed. These are directly applied to testing whether drugs reduce various soluble forms of amyloid as well as whether they enhance elimination of material deposited in brain parenchyma. The ideal profile of a drug that can fully test the amyloid hypothesis can be understood in terms of effects on currently available and future biomarkers. Dose selection for clinical trials should require a quantitative threshold effect on the most relevant biomarker.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Miller, G. 2009. Neuroscience Methods, Alzheimer’s biomarker initiative hits its stride. Science 326: 386–389.
Siemers, E., Skinner, M., Dean, R.A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., and May, P.C. 2005. Safety, tolerability, and changes in amyloid ? concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126–132.
Rosen, L.B., Stone, J.A., Plump, A., Yuan, J., Harrison, T., Flynn, M., Dallob, A., Matthews, C., Stevenson, D., Schmidt, D., et al. 2006. O4-03-02: The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimer’s and Dementia 2:S79–S79.
Bateman, R.J., Siemers, E.R., Mawuenyega, K.G., Wen, G., Browning, K.R., Sigurdson, W.C., Yarasheski, K.E., Friedrich, S.W., Demattos, R.B., May, P.C., et al. 2009. A gamma-secretase inhibitor decreases amyloid-production in the central nervous system. Ann Neurol 66:48–54.
Yan, P., Bero, A.W., Cirrito, J.R., Xiao, Q., Hu, X., Want, Y., Gonzales, E., Holtzman, D.M., Lee, J-M. 2009. Characterizing the appearance and growth of amyloid plagues in APP/PS1 mice. J Neurosci 29: 10706–10714.
Bateman, R.J., Munsell, L.Y., Morris, J.C., Swarm, R., Yarasheski, K.E., and Holtzman, D.M. 2006. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12:856–861.
Bateman, R.J., Munsell, L.Y., Chen, X., Holtzman, D.M., and Yarasheski, K.E. 2007. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom 18:997–1006.
James, A.R., Nicoll, J.A.R., Barton, E., Boche, D., Neal, J.W., Ferrer, I., Thompson, P. N., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., Seubert, P., Schenk, D. and Holmes, C. 2006. A species removal After A 42 immunization. J Neuropathol Exp Neurol 65: 1040–1048
Siemers, ER, Friedrich, S., Dean RA, Sethuraman G, Demattos RB, Jennings D, Tamagnan G, Marek K, Seibyl J. 2008. Safety, tolerability and biomarker effects of an A monoclonal antibody administered to patients with Alzheimer’s disease. Alzheimer’s and Dementia: 4(Suppl 2):T774.
Siemers, E.R., Demattos, R.B., Friedrich, S., Dean, R.A., Sethuraman, G., Margaret, R., Jennings, D., Tamagnan, G., Marek, K., Seibyl, J. and Paul, S.M. 2009. Use of a monoclonal anti-Aβ antibody with biochemical and imaging biomarkers to determine amyloid plaque load in patients with Alzheimer’s Disease (AD) and control subjects. American Academy of Neurology 2009 annual meeting, Seattle, WA; IN3-2.009.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Potter, W.Z. Dose ranging for trials through biomarkers of drug effects. J Nutr Health Aging 14, 310–311 (2010). https://doi.org/10.1007/s12603-010-0070-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-010-0070-5